Archive for the ‘Uncategorized’ Category

Welcome to our world

Tuesday, February 14th, 2012

In the recent oral argument of In re Collins, App. No. 2011-1293 (Fed. Cir. 2012), Judges Moore and Reyna took the PTO to task for a sloppy rejection of a claim.   An exasperated Judge Moore would remark “I think this is a terrible rejection.  I think you all [USPTO] have done a really sloppy job.  . . . This is ridiculous.  This is a bad rejection.  There’s a good rejection you could have made.  This isn’t it.”   [Listen] and [Listen].  I suspect that patent prosecutors everywhere who have had to explain sloppy rejections to their clients are thinking to themselves “Welcome to my world, Judges Moore and Reyna.”

Judge Moore would remark that she probably shouldn’t say that the PTO did a sloppy job and that she appreciates that the PTO is stressed and trying to incorporate new appellate judges.  However, my take is that if the PTO is not put on notice when it is doing a sloppy job, it can’t improve itself.  So, hats off to Judge Moore for calling it as she sees it.

The panel issued a Rule 36 opinion, presumably finding that the deferential standard that must be applied to Board decisions required an affirmance.

You can listen to the entire oral argument here: [Listen].

You can read the court’s opinion here: [Read].

San Diego Public Hearing for Genetic Diagnostic Patents — March 9th

Monday, February 13th, 2012

There will be a second public hearing for purposes of the study on Genetic Diagnostic Patents.  It is scheduled for San Diego in March.  The PTO has posted the schedule for pre-registered and unregistered comments:

Public Hearing on Genetic Diagnostic Testing

University of San Diego
5998 Alcalá Park San Diego, CA 92110-2492

Friday, March 9, 2012
9:00 a.m. – 4:00 p.m.

Agenda
WebEx Information Event number: 996 692 518 Event password: 123456 Event address for attendees: https://uspto-events.webex.com/uspto-events/onstage/g.php?d=996692518&t=a

Teleconference information
Call-in toll number (US/Canada): +1(408) 600 – 3600 Access code: 996 692 518

United States Patent and Trademark Office Panel
Teresa Stanek Rea, Deputy Under Secretary of Commerce for Intellectual Property and Deputy Director of the United States Patent and Trademark Office
Janet Gongola, Patent Reform Coordinator
Stuart Graham, Chief Economist
George Elliott, Technology Center Director (Biotechnology)

9:00 AM: Welcoming Remarks
Teresa Stanek Rea, Deputy Under Secretary of Commerce for Intellectual Property and Deputy Director of the United States Patent and Trademark Office
9:10 AM: Opening Commentary (Video)
Congresswoman Debbie Wasserman Schultz, U.S. House of Representatives
9:20 AM: General Commentary for Congressionally-Mandated Studies Under the AIA
Janet Gongola, Patent Reform Coordinator
9:25 AM: Overview of Genetic Diagnostic Testing Study
Stuart Graham, Chief Economist

9:35 AM: Scheduled Testimony
9:35 – 9:50 AM Mercedes Meyer, Member, Board of Directors, American Intellectual Property Law Association
9:50 – 10:05 AM Richard Marsh, Executive Vice President, General Counsel and Secretary, Myriad Genetics
10:05 – 10:25 AM Christopher Holman, Associate Professor of Law, University of Missouri-Kansas City School of Law
10:25 – 10:40 AM Carlos Candeloro, Patent Attorney (Biotechnology)
10:40 – 10:55 AM Break
10:55 – 12:00 PM Open Floor for Unscheduled Testimony
12:00 PM: Break for Lunch
1:30 PM: Open Floor for Unscheduled Testimony (continued)
Closing Remarks Janet Gongola, Patent Reform Coordinator

Public Hearing on Genetic Diagnostic Testing Patents

Saturday, February 11th, 2012

The PTO has posted the initial schedule for the first public hearing on genetic diagnostic testing patents.  Note that there is time allotted for those who did not pre-schedule their testimony, in case you missed the deadline.

Public Hearing on Genetic Diagnostic Testing

United States Patent and Trademark Office (USPTO)

600 Dulany Street, Alexandria VA

Madison Auditorium

 

 

Thursday, February 16, 2012

9:00 a.m. – 4:00 p.m.

Agenda

WebEx Information

Event number: 992 693 923 Event password: 123456 Event address for attendees: https://uspto-events.webex.com/uspto-events/onstage/g.php?d=992693923&t=a

Teleconference information

Call-in toll number (US/Canada): +1(408) 600 – 3600 Access code: 992 693 923

United States Patent and Trademark Office Panel

Teresa Stanek Rea, Deputy Under Secretary of Commerce for Intellectual Property and Deputy Director of the United States Patent and Trademark Office

Dana Robert Colarulli, Director, Office of Governmental Affairs

Janet Gongola, Patent Reform Coordinator

Stuart Graham, Chief Economist

George Elliott, Technology Center Director (Biotechnology)

9:00 AM: Welcoming Remarks

Teresa Stanek Rea, Deputy Under Secretary of Commerce for Intellectual Property and Deputy Director of the United States Patent and Trademark Office

9:10 AM: Opening Commentary (Video)

Congresswoman Debbie Wasserman Schultz, U.S. House of Representatives

9:20 AM: General Commentary for Congressionally-Mandated Studies Under the AIA

Janet Gongola, Patent Reform Coordinator

9:25 AM: Overview of Genetic Diagnostic Testing Study

Stuart Graham, Chief Economist

9:35 AM: Scheduled Testimony

9:35 – 10:05 AM

Thomas Kowalski, Shareholder, Vedder Price, P.C.

10:05 – 10:20 AM

Mercedes Meyer, Member, Board of Directors, American Intellectual Property Law Association

10:20 – 10:35 AM

Break

10:35 – 10:45 AM

Mary Williams, Executive Director, Association for Molecular Pathology

10:45 – 11:00 AM

Lori Pressman, Independent Consultant on Technology Transfer

11:00 – 11:15 AM

Hans Sauer, Associate General Counsel for Intellectual Property, Biotechnology Industry Organization

11:15 – 11:25 AM

Ellen Jorgensen, President, Genspace

11:25 – 11:35 AM

Lawrence Horn, CEO, MPEG LA, LLC Kristin Neuman, Executive Director, Librassay™, MPEG LA, LLC

11:35 – 11:45 AM

Lisa Schlager, Vice President, Community Affairs & Public Policy, FORCE

11:45 – 12:05 AM

Kevin Noonan, Partner, McDonnell Boehnen Hulbert & Berghoff LLP

 

12:05 PM: Break for Lunch

1:30 PM: Open Floor for Unscheduled Testimony

Closing Remarks      Janet Gongola, Patent Reform Coordinator

HTC Corp. v. IPCom

Saturday, February 11th, 2012

The oral argument in HTC Corp. v. IPCom, App. No. 2011-1004 (Fed. Cir. 2012) is an interesting oral argument that focuses on claim construction issues.  The case is also a good example of how the word “that” can be dangerous in drafting claims.

An exemplary claim at issue was claim 1:

A mobile station for use with a network including a first base station and a second base station that achieves a handover from the first base station to the second base station by:

storing link data for a link in a first base station, holding in reserve for the link resources of the first base station, and

when the link is to be handed over to the second base station:

initially maintaining a storage of the link data in the first base station,

initially causing the resources of the first base station to remain held in reserve, and

at a later timepoint determined by a fixed period of time predefined at a beginning of the handover, deleting the link data from the first base station and freeing up the resources of the first base station, the mobile station comprising:

an arrangement for reactivating the link with the first base station if the handover is unsuccessful.

The point of contention was whether the word “that” referred back to “mobile station” or referred back to “network.” 

For clarity, the court enumerated the claim elements as follows:

[1] A mobile station for use with a network including a first base station and a second base station that achieves a handover from the first base station to the second base station by:

[2] storing link data for a link in a first base station,

[3] holding in reserve for the link resources of the first base station, and

[4] when the link is to be handed over to the second base station:

[5] initially maintaining a storage of the link data in the first base station,

[6] initially causing the resources of the first base station to remain held in reserve, and

[7] at a later timepoint . . . deleting the link data from the first base station and freeing up the resources of the first base station, the mobile station comprising:

[8] an arrangement for reactivating the link with the first base station if the handover is unsuccessful.

The court concluded that the word “that” referred back to the word network and that the six functions in paragraphs 2-7 merely define the environment in which the mobile station operates.  

I’m left wondering if the patent owner won the battle but lost the war.  It strikes me that the claim now boils down to:

A mobile station … comprising:

an arrangement for reactivating the link with the first base station if the handover is unsuccessful.

As you can see, the newly construed claim is a single means plus function claim.  (And, if you had any doubt, the opinion notes that the parties agreed that the claim element is a means plus function element.)  Section 112, paragraph 6 permits combination claims to use means plus function language; but, the court recognized in In re Hyatt, 708 F.2d 712 (Fed. Cir. 1983)  that single means claims are invalid under section 112, paragraph 6.

You can listen to the oral argument [here].

You can read the court’s opinion here: [Read].

Deadline is TODAY to Register to Present Oral Testimony at Genetic Diagnostic Testing Hearings

Wednesday, February 8th, 2012

With the flurry of activity surrounding the implementation of the AIA, it is easy to miss some of the announcements about public hearings and the opportunity for public comment.  One of my biotech colleagues pointed out to me that TODAY is the deadline to register to present oral testimony concerning the PTO’s required study of genetic diagnostic testing.

To register to present oral testimony at either the hearing in Washington, D.C. on February 16, 2012 or in San Diego on March 9, 2012, my understanding is that one should email the following information to Saurabh Vishnubhakat at saurabh.vishnubhakat@uspto.gov: (1) The name of the person wishing to testify; (2) the person’s contact information (telephone number and email address); (3) the organization(s) the person represents, if any; (4) an indication of the amount of time needed for the testimony; and (5) a preliminary written copy of the testimony. The PTO noted that the public hearings would be made available via a webcast.

For more information on the hearings and the PTO press release see this link on the PatentDocs blog.

Judge Wallach Hears First Oral Argument as a Federal Circuit Judge

Monday, February 6th, 2012

Judge Wallach Being Sworn In Back in November

Judge Wallach Being Sworn In Back in November

 

Judge Fogel

Judge Fogel

The Federal Circuit’s newest member, Circuit Judge Evan Wallach, took part in his first oral argument as a judge on the United States Court of Appeals for the Federal Circuit today.  Chief Judge Rader was the presiding judge on the panel and welcomed Judge Wallach.  Judge Jeremy Fogel of the Northern District of California and the new Director of the Federal Judicial Center is sitting by designation with the Federal Circuit this month; and, Chief Judge Rader offered kind remarks towards Judge Fogel, as well: [Listen].

My understanding is that Judge Wallach did not take part in the en banc oral arguments of Akamai v. Limelight and McKesson v. Epic  which were argued shortly after his swearing-in in November — however, he is entitled to serve on the en banc panels that will decide those cases.  Decisions in those cases are forthcoming.

Director Kappos Testifying Before Congress on Prior User Rights

Wednesday, February 1st, 2012

The Honorable David Kappos is testifying before the House Subcommittee on the Judiciary today in a hearing titled “Prior User Rights: Strengthening U.S. Manufacturing and Innovation.”  Other notable witnesses testifying are Bob Armitage (General Counsel of Eli Lilly and Co.), Dennis Crouch (needs no introduction), Dan Lang (Vice President for Intellectual Property at Cisco Systems), and Dr. John C. Long (Vice President of Assoc. of American Universities).

You can watch the hearing [here].

You can view the speakers’ written statements at this [link] by selecting each speaker’s name.

Interesting to note that the Federal Circuit recently granted en banc review of an intervening rights case but without supplemental briefing by the parties or oral argument.  Amicus briefs are allowed and due by February 10th.  So, to the extent any relevant issues are raised by these hearings, they will have to be brought to the attention of the court by the amici rather than the parties.

USPTO Road Show in Denver on February 16th

Monday, January 30th, 2012

If your travels bring you near Denver on February 16th, note that the PTO will be conducting a road show at The University of Denver, Sturm College of Law:

United States Patent and Trademark Road Show 2012
February 16, 2012
University of Denver, Sturm College of Law

Time Event
9:00 – 9:45 REGISTRATION/NETWORKING BREAKFAST
9:45 – 10:00 WELCOME & INTRODUCTIONS
10:00 – 10:45 PATENT REFORM 2012:  UPDATE ON THE AMERICA INVENTS ACT
Discussion by USPTO officials regarding the impact and implementation of the America Invents Act (AIA) by the United States Patent and Trademark Office.
10:50 – 12:00 GETTING INTO THE ACT:  THIRD PARTY PROCEDURES
Moderated panel considering current and anticipated third party procedures, with an emphasis on the new post-grant review and opposition process introduced by the AIA and best practices in advising clients contemplating third party procedures
12:00 – 12:30 LUNCH BREAK
12:30 – 1:55 REEXAMINATION:  FROM BASICS TO BEST PRACTICES
Moderated panel considering the state of reexaminations before the USPTO, from both an administrative and litigation perspective, with an emphasis on prospective changes in view of the AIA.
2:00 – 3:00 BROADENING THE BASE:  BEST PRACTICES IN REISSUES
Discussion by USPTO officials regarding best practices before the USPTO related to patent reissues.
3:10 – 4:25 ON THE FAST TRACK:  ACCELERATED PROCESSES DURING EXAMINATION
Discussion by USPTO officials regarding accelerated patent prosecution processes, including traditional accelerated process, Track 1 examinations, pilot programs under the AIA, and the Patent Prosecution Highway.
4:30 – 5:30 STATE OF THE UNION:  LEGAL UPDATE ON KSR AND BILKSI ISSUES
Moderated panel considering the state of obviousness and subject matter patentability.
5:30 – 6:30 COCKTAIL RECEPTION 

Speakers include:

Remy Yucel. Remy Yucel is a Group Director in Technology Center 1600 whose subject matter area comprises biotechnology, biochemistry, organic chemistry and pharmaceutical patent applications. Ms. Yucel has been with United States Patent and Trademark Office since 1996 and was named Group Director in April 2008. She is also the Director of the Central Reexamination Unit (CRU). Ms. Yucel is the recipient of several Department of Commerce Awards including the Bronze Medal and the Performance Excellence Award. Prior to becoming a Director, Ms. Yucel was an examiner, primary examiner and supervisory patent examiner in the biotechnological arts; with particular emphasis on gene regulation, gene therapy and transgenic organisms.

Jean C. Witz. Jean Witz joined the USPTO in 1988 as a Patent Examiner and examined a variety of applications covering subject matter as diverse as cosmetics, pharmaceuticals and therapeutic treatments. In 2000, she was awarded a Bronze Medal for superior federal service, and in 2005, she was awarded an Exceptional Career Award for exceptional performance and service. In 2001, Ms. Witz also earned AIPLA recognition for outstanding contribution to the integrity of intellectual property law.

Amicus Briefs to Be Accepted for Marine Polymer v. Hemcon

Friday, January 27th, 2012

The Federal Circuit announced yesterday that it will be accepting amicus briefs in the en banc appeal of the intervening rights case Marine Polymer Technologies, Inc. v. Hemcon, Inc.  When the court announced the granting of en banc review last week, it noted that there would be no supplemental briefing by the parties nor oral argument.  But, amicus briefs will be accepted and are due very soon:  February 10, 2012.  [Order].

Grandmothers are off-limits

Monday, January 23rd, 2012

Oral argument was running along smoothly for this advocate when she happened to throw in an extraneous fact that the one person purported to evidence actual confusion in a trademark case was a grandmother.  Whether in jest or in defense of grandmothers everywhere, Judge Lourie noted that there was nothing the matter with grandmothers, producing this somewhat humorous exchange:  [Listen].

I thought there might be a nice quote about grandmothers that would make a fitting addition to this post.  I didn’t find what I was looking for.  But, I did find these:

My grandmother started walking five miles a day when she was sixty. She’s ninety-seven now, and we don’t know where the hell she is. ~Ellen DeGeneres

My grandmother is over eighty and still doesn’t need glasses. Drinks right out of the bottle. ~Henry Youngman

I want to die in my sleep like my grandfather – not screaming and yelling like the passengers in his car. ~Will Shriner

Oral Argument of the Month

Wednesday, January 18th, 2012

The oral argument of the month is Ledergerber Medical v. WL Gore, case no. 2011-1379 (Fed. Cir. 2012).  The majority of the argument features the advocates fielding questions from the judges about priority chains under 35 U.S.C. sections 120, 112 and 103.  It appeared to be an opportunity for Judge Newman to reassert her view from her dissenting opinion in Zenon Environmental, Inc. v. US Filter Corp., 506 F. 3d 1370 (Fed. Cir. 2007).  In that dissent she said “I respectfully dissent, for my colleagues have converted fact into law and ignored the findings of the district court as well as the agreed and undisputed facts, and misapplied the rules of incorporation by reference. The consequence is that the disclosure in the “grandparent” (‘373) patent is held by this court to “anticipate” and thereby invalidate the “grandchild” (‘319) patent that contains the text of the ‘373 patent.”

You can listen to the oral argument [here].

The court issued a Rule 36 opinion; but, look for the appellant to request en banc review.

Judicial Takings and Patent Law

Saturday, January 14th, 2012

In 2010, the Supreme Court decided STOP THE BEACH RENOURISHMENT. v. FLA. DEPT. OF ENV. PROT., 130 S. Ct. 2592 (2011). [Opinion] [Oral Argument via OYEZ]. This opinion raises an interesting academic issue with respect to patent law. Can the federal judiciary unfairly take a patent right in violation of the Takings Clause of the Fifth Amendment? According to Justice Scalia’s plurality opinion (on behalf of himself, C.J. Roberts, and Justices Thomas and Alito), it would appear one might make such an argument. Justice Scalia writes, with respect to taking by a state court:

In sum, the Takings Clause bars the State from taking private property without paying for it, no matter which branch is the instrument of the taking. To be sure, the manner of state action may matter: Condemnation by eminent domain, for example, is always a taking, while a legislative, executive, or judicial restriction of property use may or may not be, depending on its nature and extent. But the particular state actor is irrelevant. If a legislature or a court declares that what was once an established right of private property no longer exists, it has taken that property, no less than if the State had physically appropriated it or destroyed its value by regulation. “[A] State, by ipse dixit, may not transform private property into public property without compensation.” Ibid.

Justice Scalia gave as one example, the State of Florida ipse dixit recharacterizing the principal funds of an account as “public” money when it was actually private money:

Webb’s Fabulous Pharmacies, supra, is even closer in point. There the purchaser of an insolvent corporation had interpleaded the corporation’s creditors, placing the purchase price in an interest-bearing account in the registry of the Circuit Court of Seminole County, to be distributed in satisfaction of claims approved by a receiver. The Florida Supreme Court construed an applicable statute to mean that the interest on the account belonged to the county, because the account was “considered ‘public money,'” Beckwith v. Webb’s Fabulous Pharmacies, 374 So.2d 951, 952-953 (1979) (per curiam). We held this to be a taking. We noted that “[t]he usual and general rule is that any interest on an interpleaded and deposited fund follows the principal and is to be allocated to those who are ultimately to be the owners of that principal,” 449 U.S., at 162, 101 S.Ct. 446. “Neither the Florida Legislature by statute, nor the Florida courts by judicial decree,” we said, “may accomplish the result the county seeks simply by recharacterizing the principal as ‘public money.'” Id., at 164, 101 S.Ct. 446.

So, this raises an interesting issue with respect to patent rights. If a court wrongly recharacterizes a patent right so as to effectively dedicate it to the public, has the court executed a judicial taking? As an example, did the court in In re Abele, 684 F.2d 902 (1982) execute a judicial taking by recharacterizing an apparatus claim as a method claim and then invalidating the recharacterized claim as an abstract idea?  In In re Abele, the CCPA effectively rewrote an apparatus claim as a method claim as shown below:

Original Claim 7 Recharacterized claim 7
7. Apparatus for displaying data values representative of values at data points in a two dimensional field comprising:  7R.  A method Apparatus for displaying data values representative of values at data points in a two dimensional field comprising: 
means for calculating the differences between the local values at each data point and the average value at data points in a limited region of said field surrounding each said data point, and  means for calculating the differences between the local values at each data point and the average value at data points in a limited region of said field surrounding each said data point, and 
means for displaying the value of said differences as signed gray scale values at points in a picture which correspond to said data points. means for displaying the value of said differences as signed gray scale values at points in a picture which correspond to said data points.

The CCPA said in In re Abele:

Appellants do not argue and, in any event, we see no basis for treating their apparatus claims differently from their method claims.

If the functionally-defined disclosed means and their equivalents are so broad that they encompass any and every means for performing the recited functions, the apparatus claim is an attempt to exalt form over substance since the claim is really to the method or series of functions itself. In computer-related inventions, the recited means often perform the function of “number crunching” (solving mathematical algorithms and making calculations). In such cases the burden must be placed on the applicant to demonstrate that the claims are truly drawn to specific apparatus distinct from other apparatus capable of performing the identical functions.If this burden has not been discharged, the apparatus claim will be treated as if it were drawn to the method or process which encompasses all of the claimed “means.” [In re Walter, 618 F.2d at 768, 205 USPQ at 408.]Thus, claim 7, the apparatus counterpart to claim 5, suffers the same defects as does claim 5.

Clearly, the court recharacterized the apparatus claim as a method claim.  After doing so, the court’s subsequent analysis found the claim to be ineligible subject matter as a mathematical algorithm.  Thus, one could argue that the recharacterized claim was taken from a private entity and it inured to the benefit of the public.  (One can debate whether the invalidation of a patent claim is a conveyance to the public, since a patent right is a right to exclude others from practicing the claim rather than a right to be able to practice the claim – nevertheless, the public is less encumbered when a patent claim is invalidated.) 

So, what about the CyberSource Corp. v. Retail Decisions, Inc. case?  In that case, the panel recharacterized a claim directed to a physical article as a method claim.  The panel effectively rewrote the article of manufacture claim as follows:

Original Claim 2 Recharacterized Claim 2
2. A computer readable medium containing program instructions for detecting fraud in a credit card transaction between a consumer and a merchant over the Internet, wherein execution of the program instructions by one or more processors of a computer system causes the one or more processors to carry out the steps of:  2R. A computer readable medium containing program instructions method for detecting fraud in a credit card transaction between a consumer and a merchant over the Internet, wherein execution of the program instructions by one or more processors of a computer system causes the one or more processors to carry out the steps of comprising
a) obtaining credit card information relating to the transactions from the consumer; and  a) obtaining credit card information relating to the transactions from the consumer; and 
b) verifying the credit card information based upon values of plurality of parameters, in combination with information that identifies the consumer, and that may provide an indication whether the credit card transaction is fraudulent,  b) verifying the credit card information based upon values of plurality of parameters, in combination with information that identifies the consumer, and that may provide an indication whether the credit card transaction is fraudulent, 
wherein each value among the plurality of parameters is weighted in the verifying step according to an importance, as determined by the merchant, of that value to the credit card transaction, so as to provide the merchant with a quantifiable indication of whether the credit card transaction is fraudulent,  wherein each value among the plurality of parameters is weighted in the verifying step according to an importance, as determined by the merchant, of that value to the credit card transaction, so as to provide the merchant with a quantifiable indication of whether the credit card transaction is fraudulent, 
wherein execution of the program instructions by one or more processors of a computer system causes that one or more processors to carry out the further steps of;  wherein execution of the program instructions by one or more processors of a computer system causes that one or more processors to carry out the further steps of; and further comprising 
[a] obtaining information about other transactions that have utilized an Internet address that is identified with the credit card transaction;  [a] obtaining information about other transactions that have utilized an Internet address that is identified with the credit card transaction; 
[b] constructing a map of credit card numbers based upon the other transactions; and [b] constructing a map of credit card numbers based upon the other transactions; and
[c] utilizing the map of credit card numbers to determine if the credit card transaction is valid. [c] utilizing the map of credit card numbers to determine if the credit card transaction is valid.
   

Having effectively recharacterized the article of manufacture claim as a method claim and ignored the physical limitations in the claim that tied the claim to a physical object, the panel in CyberSource concluded that the claim covered a mental process and was thus patent ineligible.  One could argue that this is another example of a taking of a private right (i.e., a taking of the patent right to the article of manufacture) and a transfer of that right to the public.  (Again, it is open to debate whether destruction of a right to exclude is a transfer to the public – but the public is certainly less encumbered after the destruction of a patent right.) 

This raises an interesting issue with respect to the petition for certiorari in CyberSource.  If the petition for cert. is denied or never filed, could CyberSource later bring a judicial takings claim against the U.S. judiciary?   Justice Scalia’s plurality opinion suggests that the remedy for a judicial taking is a restoration of the taken property back to the injured party.  In this case, that would be restoration of the article of manufacture claim.  Moreover, assuming that the statute of limitations for a judicial takings is six years, think what havoc a judicial takings policy would have if one could wait six years and then revive a patent right previously deemed invalid by a court.

Justice Scalia’s plurality opinion seems to suggest that any change in the law – not even a significant change in the law – by the judiciary that results in a property right being extinguished can result in a judicial taking.  The next time you read a precedential opinion from the court or read the fiery opening lines of a dissenting opinion, consider whether a once valid patent right has been extinguished. 

Personally, I think a judicial takings policy in the context of patent law is likely unworkable.  But, it is an interesting subject to think/argue about.

For more on judicial takings and patent law see:  S.L. Dogan and E.A. Young “Judicial Takings and Collateral Attack on State Court Property Decisions,” 6:1 Duke Journal of Constitutional Law and Policy 111, 130  (2011).

Audio of Kappos v. Hyatt Supreme Court Oral Argument

Friday, January 13th, 2012

The Supreme Court has now released the audio of Monday’s oral argument in Kappos v. Hyatt.  You can listen to the oral argument here: [Listen].

Spring Break in San Diego

Thursday, January 12th, 2012

The AIPLA has announced the date for the 2012 Electronic and Computer Patent Law Summit.  It will be held on April 2nd in San Diego.  I’ve been fortunate to be part of the planning committee this year; and, I can tell you that it is shaping up to be another great summit.  So, think about making your spring break plans around beautiful San Diego and the AIPLA summit!

Oral Argument Kappos v. Hyatt

Friday, January 6th, 2012

The oral argument in Kappos v. Hyatt is scheduled for next Monday, January 9th, at the Supreme Court of the United States.  The issues to be considered are:

(1) Can a plaintiff, who is appealing the denial of an application of a patent by commencing a civil action against the Director of the United States Patent and Trademark Office (PTO) in a federal district court pursuant to 35 U.S.C. § 145, introduce new evidence that could have been presented to the agency in the first instance?

(2) When new evidence is introduced under Section 145, can the district court decide de novo the factual questions to which the evidence pertains, without giving deference to the prior decision of the PTO?

The en banc Federal Circuit decision is available [here].